3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Thyroid Cancer, Papillary
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Bevacizumab
32
Cetuximab
28
Fluorouracil
26
Leucovorin
24
Specimen Handling
23
Oxaliplatin
23
pembrolizumab
18
Biopsy
16
Magnetic Resonance Spectroscopy
14
Irinotecan
13
Nivolumab
9
atezolizumab
7
Folfox protocol
7
fludarabine
6
balstilimab
6
Pemetrexed
6
Panitumumab
6
Cyclophosphamide
6
Cisplatin
6
Carboplatin
6
Capecitabine
6
trifluridine tipiracil drug combination
5
encorafenib
5
Standard of Care
5
IFL protocol
5
HMPL-013
5
Gemcitabine
5
dehydroftorafur
4
Immunoglobulin G
4
Disulfides
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
entrectinib
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA